



Client Services Phone: (888) 203-2725 Fax: (347) 685-1909 Email: clientservices@renalytix.com

TEST REQUISITION FORM

To avoid delays complete the entire form

ACCOUNT INFORMATION			PATIENT INFORMATION				
			PATIENT NAME (LAST, FIRST, INITIAL)				
STREET ADDRESS		PATIENT ID #/ MEDICAL	AL RECORD # FEMALE BIRTH DATE (MM/DD/YYYY)				
CITY STAT	STATE ZIP S			STREET ADDRESS			
PHONE NUMBER FAX I	NUMBER		CITY	STATE		ZIP	
DFFICE CONTACT			DAYTIME PHONE NUMBER EMAIL ADDRESS				
EMAIL ADDRESS			RACE AND ETHNICITY WHITE BLACK OR AFRICAN AMERICAN HISPANIC OR LATINO ASIAN AMERICAN INDIAN OR ALASKA NATIVE NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER				
PATIENT CLINICAL INFORMATION							
PROVIDE MOST RECENT VALUES							
Estimated Glomerular Filtration Rate (Platelet Count (x10 ³ per μL)						
Urinary Albumin to Creatinine Ratio (uACR, mg/g)							
Systolic Blood Pressure (SBP, mm of Hg) Aspartate Aminotransferase (AST, IU/Liter)							
Hemoglobin A1c (%)							
DIAGNOSIS INFORMATION (Choose one option and provide the necessary information)							
ICD-10 CODES ARE REQUIRED			☐ Insurance			ance cards. Indicate which is	
Patient has been diagnosed with Type 2 Diabetes Yes No CD-10 Code/s			☐ Self-Pay	primary. Testing may be delayed if not received with the sample. Patient will be contacted once sample is received to complete			
Patient has been diagnosed with Chronic Kidney Disease (CKD) Yes No CD-10 Code/s			☐ Client	this process and set up payment or payment plan. Client Name: Client Contact:			
Other Conditions			☐ Other Third Party	Pay Source: Contact Information:			
TEST REQUESTED							
□ KidneyIntelX [™] - is a quantitative electrochemiluminescence immunoassay using the Meso Sector S 600 instrument for measurement of soluble Tumor Necrosis Factor Receptor 1 (sTNFR1), soluble Tumor Necrosis Factor Receptor 2 (sTNFR2) and Kidney Injury Molecule-1 (kIM-1) in human plasma combined with clinical data, using an artificial intelligence-derived algorithm to produce a composite risk score. It is indicated for use as an aid to further assess the risk of progressive decline in kidney function within a period of up to 5 years in patients over the age of 21 with Type 2 diabetes and existing chronic kidney disease. Patients with chronic kidney disease will have an estimated Glomerular Filtration Rate [eGFR] of 30-59 ml/min/1.73 m [G3a, G3b] * or eGFR ≥ 60 with albuminuria [UACR] ≥ 30 mg/g [A2, A3] *.							
A progressive decline in kidney function occurs when one or more of the following conditions are observed: WARNING: Enbrel® interferes							
*Rapid Kidney Function Decline (RKFD) defined as an eGFR slope of ≥ 5 ml/min/1.73m² /year *Sustained decrease in eGFR ≥ 40% confirmed at least 3 months apart *Kidney Failure, defined by sustained eGFR < 15 ml/min/1.73m², initiation of long-term dialysis, or kidney transplantation KidneyIntelX is not intended as a screening or stand-alone diagnostic test. *KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease							
AUTHORIZED SIGNATURE							
Physician Name	Email Address						
I am a licensed medical professional. I acknowledge that the test requested herein is medically necessary and the patient is eligible for the test. I attest that the documentation of medical necessity for tests ordered is documented in the patient's medical record, which will be made available upon request of performing laboratory and/or third-party payer.							
Physician's Signature Date							
SPECIMEN INFORMATION							
DATE SAMPLE WAS TAKEN TIME S	SAMPLE WAS TAKEN	PHLEBOTOMI	ST NAME PHLEB	OTOMIST PHONE NU		LEBOTOMIST LAB NAME pplicable)	
AM □PM							